Hindsight: review of preclinical disease models for the development of new treatments for uveal melanoma
Palanga, Letizia, Goldrick, Caoimhe, Tang, Bobby, Mealy, Grace, Crown, John, Horgan, Noel, Kennedy, Susan and Walsh, NaomiORCID: 0000-0002-2178-3564
(2021)
Hindsight: review of preclinical disease models for the development of new treatments for uveal melanoma.
Journal of Cancer, 12
(15).
pp. 4672-4685.
ISSN 1837-9664
The molecular, histopathological, genomic and transcriptomic characteristics of uveal melanoma (UM) have identified four molecular subgroups with different clinical outcomes. Despite the improvements in UM classification and biological pathology, current treatments do not reduce the occurrence of metastasis. The development of effective adjuvant and metastatic therapies for UM has been slow and extremely limited. Preclinical models that closely resemble the molecular and genetic UM subgroups are essential for translating molecular findings into improved clinical treatment. In this review, we provide a retrospective view of the existing preclinical models used to study UM, and give an overview of their strengths and limitations. We review targeted therapy clinical trial data to evaluate the gap in the translation of preclinical findings to human studies. Reflecting on the current high attrition rates of clinical trials for UM, preclinical models that effectively recapitulate the human in vivo situation and/or accurately reflect the subtype classifications would enhance the translational impact of experimental data and have crucial implications for the advancement of personalised medicine.
Royal Victoria Eye and Ear Hospital Research Foundation (Annual Grant Scheme 2019) (BT/SK), IRC-Enterprise Partnership post-graduate fellowship (EPSPG/2020/401) (LP) and Cancer Clinical Research Trust (NW)
ID Code:
26373
Deposited On:
20 Oct 2021 12:38 by
Vidatum Academic
. Last Modified 20 Oct 2021 12:38